Pittsburgh-based personalized medicine company Precision Therapeutics has changed its name to Helomics Corp. – and has brought in an impressive $60 million financing round and hired a new C-suite and board, to boot. The company’s strategy will be to become highly acquisitive in the personalized medicine space, it said in a statement. The cancer diagnostics company […]
Fresh off a $34 million Series D fundraise, Precision Therapeutics Inc. is planning to launch a “genomics” product sometime in 2011. CEO Sean McDonald offered few details beyond that, however. “All of our technology is geared toward helping patients and doctors understand which treatments are likely to be most effective based on [the cancer patient’s] […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Precision Therapeutics Inc. has raised $34 million in equity and options to further develop a test that helps identify an individual’s best chemotherapy options, according to a filing with the Securities and Exchange Commission. The company’s ChemoFX drug marker tests multiple chemotherapies on a patient’s cancer cells before treatment to determine which drugs are likely […]